Notes
2016 euros
Reference
Vennera MD, et al. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical Drug Investigation : 3 May 2016. Available from: URL: http://doi.org/10.1007/s40261-016-0402-2
Rights and permissions
About this article
Cite this article
Omalizumab cost effective for severe persistent asthma. PharmacoEcon Outcomes News 753, 25 (2016). https://doi.org/10.1007/s40274-016-3058-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3058-5